NanoViricides Partners for Phase II Trial of Broad-Spectrum Antiviral NV-387 In a significant step towards fighting the global threat of monkeypox (MPox), NanoViricides Inc., a biopharmaceutical company based in Shelton, Connecticut, has joined forces with a clinical research organization to launch a Phase II clinical trial for its antiviral drug candidate, NV-387. This milestone comes […]
The post NanoViricides’ NV-387 Begins Phase II Trial for Monkeypox appeared first on News Directory 3.